Drugs / SY-3505
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06037317 | May 2024 → Dec 2025 | neoplasm | Shouyao Holdings (Beijing) Co. LTD | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05869162 | Jun 2023 → Jun 2025 | non-small cell lung carcinoma | Shouyao Holdings (Beijing) Co. LTD | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06254599 | May 2024 → May 2026 overdue | non-small cell lung carcinoma | Shouyao Holdings (Beijing) Co. LTD | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SY-3505 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06254599 ↗ |
| Action | Inhibit | “SY-3505 is a potent, brain-penetrant, third-generation ALK tyrosine kinase inhibitor (TKI)” NCT05869162 ↗ |
| Route | Oral | “600 mg once daily (QD) orally” NCT05869162 ↗ |
| Target | ALK | “SY-3505 is a potent, brain-penetrant, third-generation ALK tyrosine kinase inhibitor (TKI)” NCT05869162 ↗ |